Long-Term Outcomes with Monotherapy for LR and fIR Prostate Cancer

Long-Term Outcomes with Monotherapy for LR and fIR Prostate Cancer

Timothy N. Showalter, MD, discusses brachytherapy monotherapy for low, favorable intermediate & selected unfavorable intermediate risk PCa.